These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 6689221)
1. In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat. Maguire ED; Wallis RB Thromb Res; 1983 Oct; 32(1):15-27. PubMed ID: 6689221 [TBL] [Abstract][Full Text] [Related]
2. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides. Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780 [TBL] [Abstract][Full Text] [Related]
3. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models. Ku EC; McPherson SE; Signor C; Chertock H; Cash WD Biochem Biophys Res Commun; 1983 May; 112(3):899-906. PubMed ID: 6687803 [TBL] [Abstract][Full Text] [Related]
4. CGS 12970: a novel, long acting thromboxane synthetase inhibitor. Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197 [TBL] [Abstract][Full Text] [Related]
5. The effect of a thromboxane synthetase inhibitor, dazoxiben, and acetylsalicylic acid on platelet function and prostaglandin metabolism. Dale J; Thaulow E; Myhre E; Parry J Thromb Haemost; 1983 Oct; 50(3):703-6. PubMed ID: 6689091 [TBL] [Abstract][Full Text] [Related]
6. Comparison of radioimmunoassay and high-resolution gas chromatography mass spectrometry for the quantitative determination of serum thromboxane B2 and 6-keto-PGF1 alpha after pharmacological blockade of thromboxane synthetase. Chiabrando C; Castagnoli MN; Noseda A; Fanelli R; Rajtar G; Cerletti C; de Gaetano G Prostaglandins Leukot Med; 1984 Oct; 16(1):79-88. PubMed ID: 6440153 [TBL] [Abstract][Full Text] [Related]
7. A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats. Mallarkey G; Smith GM Br J Pharmacol; 1985 Feb; 84(2):425-30. PubMed ID: 3156648 [TBL] [Abstract][Full Text] [Related]
8. Differential effects of dazoxiben, a selective thromboxane-synthase inhibitor, on platelet and renal prostaglandin-endoperoxide metabolism. Patrignani P; Filabozzi P; Catella F; Pugliese F; Patrono C J Pharmacol Exp Ther; 1984 Feb; 228(2):472-7. PubMed ID: 6537977 [TBL] [Abstract][Full Text] [Related]
9. Selective and nonselective inhibition of thromboxane formation. FitzGerald GA; Oates JA Clin Pharmacol Ther; 1984 May; 35(5):633-40. PubMed ID: 6370554 [TBL] [Abstract][Full Text] [Related]
10. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis--effect of a thromboxane synthase inhibitor. Carter AJ; Bevan JA; Hanley SP; Morgan WE; Turner DR Thromb Haemost; 1984 Apr; 51(2):257-60. PubMed ID: 6377567 [TBL] [Abstract][Full Text] [Related]
11. Thromboxane synthase inhibitors. Synthesis and pharmacological activity of (R)-, (S)-, and (+/-)-2,2-dimethyl-6-[2-(1H-imidazol-1-yl)-1-[[(4-methoxyphenyl)- methoxy]methyl]ethoxy]hexanoic acids. Manley PW; Tuffin DP; Allanson NM; Buckle PE; Lad N; Lai SM; Lunt DO; Porter RA; Wade PJ J Med Chem; 1987 Oct; 30(10):1812-8. PubMed ID: 3656356 [TBL] [Abstract][Full Text] [Related]
12. Effects of a thromboxane synthetase inhibitor and a thromboxane antagonist on release and activity of thromboxane A2 and prostacyclin in vitro. O'Keefe EH; Liu EC; Greenberg R; Ogletree ML Prostaglandins; 1985 May; 29(5):785-97. PubMed ID: 3925501 [TBL] [Abstract][Full Text] [Related]
13. Effects of thromboxane synthetase inhibition on arachidonate metabolism and platelet behaviour. Parry MJ Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):23S-29S. PubMed ID: 6401997 [TBL] [Abstract][Full Text] [Related]
14. Selective inhibition of thromboxane synthetase with dazoxiben - basis of its inhibitory effect on platelet adhesion. Menys VC; Davies JA Thromb Haemost; 1983 Apr; 49(2):96-101. PubMed ID: 6346575 [TBL] [Abstract][Full Text] [Related]
15. Effects of flunixin meglumine, phenylbutazone and a selective thromboxane synthetase inhibitor (UK-38,485) on thromboxane and prostacyclin production in healthy horses. Hardee MM; Moore JN; Hardee GE Res Vet Sci; 1986 Mar; 40(2):152-6. PubMed ID: 3517992 [TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of UK 37248, a thromboxane synthetase inhibitor, in experimental endotoxic shock in the rat. Halushka PV; Cook JA; Wise WC Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):133S-139S. PubMed ID: 6337604 [TBL] [Abstract][Full Text] [Related]
17. The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK-38,485, on prostanoid formation in man. Fischer S; Struppler M; Böhlig B; Bernutz C; Wober W; Weber PC Circulation; 1983 Oct; 68(4):821-6. PubMed ID: 6352080 [No Abstract] [Full Text] [Related]
18. Effects of a thromboxane synthetase inhibitor on platelet function; possible risks of use in pregnancy. Sullivan MH; Ahmed Y; Elder MG Prostaglandins; 1993 Jul; 46(1):21-6. PubMed ID: 8378539 [TBL] [Abstract][Full Text] [Related]
19. The effect of a thromboxane synthetase inhibitor, OKY-046, on urinary excretion of immunoreactive thromboxane B2 and 6-keto-prostaglandin F1 alpha in patients with ischemic cerebrovascular disease. Uyama O; Nagatsuka K; Nakabayashi S; Isaka Y; Yoneda S; Kimura K; Abe H Stroke; 1985; 16(2):241-4. PubMed ID: 3883580 [TBL] [Abstract][Full Text] [Related]
20. The effects of a new thromboxane synthetase inhibitor, CGS-13080, in man. MacNab MW; Foltz EL; Graves BS; Rinehart RK; Tripp SL; Feliciano NR; Sen S J Clin Pharmacol; 1984; 24(2-3):76-83. PubMed ID: 6371062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]